Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib

Por Press, Richard D., Willis, Stephanie G., Laudadio, Jennifer, Mauro, Michael J., Deininger, Michael W. N.
Publicado em 2009

Molecular Phylogenetic and Biogeochemical Studies of Sulfate-Reducing Bacteria in the Rhizosphere of Spartina alterniflora

Por Hines, Mark E., Evans, Robert S., Sharak Genthner, Barbara R., Willis, Stephanie G., Friedman, Stephanie, Rooney-Varga, Juliette N., Devereux, Richard
Publicado em 1999

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

Por Bradeen, Heather A., Eide, Christopher A., O'Hare, Thomas, Johnson, Kara J., Willis, Stephanie G., Lee, Francis Y., Druker, Brian J., Deininger, Michael W.
Publicado em 2006

Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph(+)ALL: a Children’s Oncology Group (COG) study

Por Chang, Bill H, Willis, Stephanie G, Stork, Linda, Hunger, Stephen P, Carroll, William L, Camitta, Bruce M, Winick, Naomi J, Druker, Brian J, Schultz, Kirk R
Publicado no Br J Haematol (2012)

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

Por Agarwal, Anupriya, Bumm, Thomas G. P., Corbin, Amie S., O'Hare, Thomas, Loriaux, Marc, VanDyke, Jonathan, Willis, Stephanie G., Deininger, Jutta, Nakayama, Keiichi I., Druker, Brian J., Deininger, Michael W.
Publicado em 2008

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

Por Tyner, Jeffrey W., Walters, Denise K., Willis, Stephanie G., Luttropp, Mary, Oost, Jason, Loriaux, Marc, Erickson, Heidi, Corbin, Amie S., O'Hare, Thomas, Heinrich, Michael C., Deininger, Michael W., Druker, Brian J.
Publicado em 2008

RNAi screen for rapid therapeutic target identification in leukemia patients

Por Tyner, Jeffrey W., Deininger, Michael W., Loriaux, Marc M., Chang, Bill H., Gotlib, Jason R., Willis, Stephanie G., Erickson, Heidi, Kovacsovics, Tibor, O'Hare, Thomas, Heinrich, Michael C., Druker, Brian J.
Publicado em 2009

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

Por Tyner, Jeffrey W., Erickson, Heidi, Deininger, Michael W. N., Willis, Stephanie G., Eide, Christopher A., Levine, Ross L., Heinrich, Michael C., Gattermann, Norbert, Gilliland, D. Gary, Druker, Brian J., Loriaux, Marc M.
Publicado em 2009

A gene expression signature of CD34(+) cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Por McWeeney, Shannon K., Pemberton, Lucy C., Loriaux, Marc M., Vartanian, Kristina, Willis, Stephanie G., Yochum, Gregory, Wilmot, Beth, Turpaz, Yaron, Pillai, Raji, Druker, Brian J., Snead, Jennifer L., MacPartlin, Mary, O'Brien, Stephen G., Melo, Junia V., Lange, Thoralf, Harrington, Christina A., Deininger, Michael W. N.
Publicado em 2010

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Por Levine, Ross L., Loriaux, Marc, Huntly, Brian J. P., Loh, Mignon L., Beran, Miroslav, Stoffregen, Eric, Berger, Roland, Clark, Jennifer J., Willis, Stephanie G., Nguyen, Kim T., Flores, Nikki J., Estey, Elihu, Gattermann, Norbert, Armstrong, Scott, Look, A. Thomas, Griffin, James D., Bernard, Olivier A., Heinrich, Michael C., Gilliland, D. Gary, Druker, Brian, Deininger, Michael W. N.
Publicado em 2005